Nanogap Therapeutics

We are developing a novel treatment for mutant KRAS cancer, which is 30% of all cancers and is resistant to current therapies .

  • Stage Product In Development
  • Industry Biotechnology
  • Location Santiago de Compostela, Spain
  • Currency EUR
  • Founded July 2019
  • Employees 2
  • Incorporation Type Other
  • Website nanpgaptherapeutics.com

Company Summary

We are developing the first-in-class therapeutic agent to cancers drivel by high levels of reactive oxygen species. This group contains KRAS mutant cancer and primary brain cancer, and is over 30% of all cancers. We have a completely novel MOA and robust IP protection.
We are seeking funding to enable manufacturing process development and of preclinical work to support a series A round next year, with the aim of a first-in-human trial in 2021.

Team

  • Ross Breckenridge

  • Fernando Dominguez
    Scientific Advisor, Scientific Founder

    Full Professor at University of Santiago de Compostela, Spain. Director of Galician Oncology Research Center.

  • Graeme R. Martin Ph.D.
    Board Director

    Formerly CEO Takeda Ventures Inc., as well as senior positions in R+D in several pharmaceuticals. Now Principal, HatchBox Bioconsulting LLC.

  • Darren Bianchi Bianchi
    Board Director

    CEO, Brilliant Group and President, NANOGAP USA.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free